Bausch + Lomb Corporation (BLCO) AI Stock Analysis

• Market Cap: $4.91B
• Dividend Yield: N/A
• Average Volume (3M): 705.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: 11.94%
• EPS Growth: -6.98%
• Country: US
• Employees: 13,500
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.07
• Shares Outstanding: 353,396,640
• 10 Day Avg. Volume: 506,504
• 30 Day Avg. Volume: 705,729
• PEG Ratio: 0.75
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -28.88
• Enterprise Value/Market Cap: 1.93
• Enterprise Value/Revenue: 0.50
• Enterprise Value/Gross Profit: 3.44
• Enterprise Value/Ebitda: 4.32
• 1Y Price Target: $13.89
• Price Target Upside: -0.29% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 10

• Rating: 64 Neutral
• Price Target: $14.50 ▲(4.09%Upside)

Bausch + Lomb's stock score is primarily influenced by its financial performance and technical analysis. While the company shows strong market positioning and growth in key segments, profitability and cash flow issues weigh heavily. Technical indicators are favorable, but nearing overbought levels. The valuation remains weak, primarily due to negative earnings. However, recent corporate events and resilient earnings call outcomes provide some positive outlook.

Positive Factors

Earnings

Miebo sales beat expectations in Q1, significantly outperforming both the analyst's estimate and consensus.

Product Performance

Miebo TRx continues to trend strong, with weekly averages significantly up from Q1, indicating strong momentum for the drug.

Revenue Growth

Management raised 2025 revenue guidance to $5.0-$5.1B, reflecting a positive outlook for the company's financial performance.

Negative Factors

Competition

Miebo and Xiidra together saw a slight decline in their dry eye new prescription share, which could indicate increasing competition in the market.

Financial Performance

The stock is under pressure after a guidance cut and the reiteration of an underperform rating.

Operational Challenges

The enVista recall negatively impacts revenue and EBITDA in 2025, despite the issue being resolved and production resuming.

Bausch + Lomb Corporation Business Overview & Revenue Model

Company Description

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

How the Company Makes Money

Bausch + Lomb makes money through a diversified revenue model centered around its key product categories. The Vision Care segment generates revenue from the sale of contact lenses and lens care products, catering to both individual consumers and eye care professionals. The Pharmaceuticals segment includes prescription and over-the-counter products for the treatment of various eye conditions, contributing significantly to the company's earnings. The Surgical segment derives its income from the sale of ophthalmic surgical devices and instruments, which are used in procedures such as cataract surgery. Bausch + Lomb's revenue streams are supported by its global distribution network and strategic partnerships with healthcare providers and institutions, enabling it to maintain a strong presence in the eye health market.

Bausch + Lomb Corporation Financial Statement Overview

Summary

Bausch + Lomb demonstrates solid revenue growth and strong gross margins. However, profitability challenges due to negative net income margins and declining EBIT margin, along with cash flow constraints, pose significant challenges. The stable balance sheet mitigates some risks.

Income Statement

Bausch + Lomb Corporation shows a consistent revenue growth trajectory, with a 3.5% increase in TTM. However, the company is facing profitability challenges, as indicated by negative net income margins and a declining EBIT margin. The gross profit margin remains strong at approximately 66.9%, but the company needs to address its operational inefficiencies to improve its overall profitability.

Balance Sheet

The company maintains a solid equity base with an equity ratio of 47.4%, indicating financial stability. However, the debt-to-equity ratio of 0.76 suggests moderate leverage, which could pose risks if profitability does not improve. The return on equity is negative due to net losses, highlighting the need for enhanced operational performance.

Cash Flow

The cash flow analysis reveals a concerning trend with negative free cash flow in the TTM period, indicating challenges in generating cash after capital expenditures. Operating cash flow is positive but declining, with a significant drop in the operating cash flow to net income ratio. The company must improve its cash generation capabilities to ensure long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.83B	4.77B	4.15B	3.77B	3.77B	3.41B
Gross Profit	2.75B	2.90B	2.50B	2.25B	2.30B	2.13B
EBITDA	399.00M	614.00M	512.00M	599.00M	762.00M	739.00M
Net Income	-490.00M	-317.00M	-260.00M	15.00M	182.00M	-17.00M
Balance Sheet
Total Assets	13.43B	13.47B	13.44B	11.14B	10.82B	11.27B
Cash, Cash Equivalents and Short-Term Investments	202.00M	305.00M	331.00M	354.00M	174.00M	238.00M
Total Debt	4.83B	4.78B	4.56B	2.44B	112.00M	101.00M
Total Liabilities	7.00B	6.92B	6.52B	4.04B	1.42B	1.28B
Stockholders Equity	6.36B	6.47B	6.85B	7.03B	9.33B	9.92B
Cash Flow
Free Cash Flow	-167.41M	-59.00M	-198.00M	170.00M	664.00M	263.00M
Operating Cash Flow	165.60M	232.00M	-17.00M	345.00M	873.00M	522.00M
Investing Cash Flow	-470.07M	-412.00M	-2.11B	-215.00M	-214.00M	-256.00M
Financing Cash Flow	196.63M	178.00M	2.08B	81.00M	-712.00M	-232.00M

Bausch + Lomb Corporation Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.93
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLCO, the sentiment is Positive. The current price of 13.93 is above the 20-day moving average (MA) of 13.52, above the 50-day MA of 12.46, and below the 200-day MA of 15.85, indicating a neutral trend. The MACD of 0.49 indicates Negative momentum. The RSI at 67.51 is Neutral, neither overbought nor oversold. The STOCH value of 60.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLCO.

Bausch + Lomb Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	83 Outperform	$37.82B	28.96	25.81%	0.79%	9.54%	37.23%
COO	69 Neutral	$14.49B	34.59	5.15%	―	6.88%	21.11%
BLCO	64 Neutral	$4.91B	―	-5.56%	―	11.94%	-6.98%
XRAY	62 Neutral	$3.12B	―	-34.47%	4.88%	-5.61%	-921.99%
BAX	56 Neutral	$14.12B	136.07	-8.96%	3.96%	-20.17%	-138.32%
Sector *	52 Neutral	$7.45B	-0.04	-63.76%	2.49%	16.24%	<0.01%
STAA	51 Neutral	$859.77M	55.81	-19.14%	―	-14.44%	-557.38%

Bausch + Lomb Corporation Corporate Events

Bausch + Lomb Expands Note Offering to €675 Million

On June 18, 2025, Bausch + Lomb Corporation announced an increase in its offering of senior secured floating rate notes to €675 million, up from €600 million, with the proceeds intended to refinance existing loans and credit facilities. The company is also seeking to establish a $2.325 billion new term B loan facility and a new $800 million revolving credit facility, with both expected to close on June 26, 2025, to further strengthen its financial position.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Bausch + Lomb Launches €600 Million Notes Offering

On June 10, 2025, Bausch + Lomb Corporation announced the launch of a €600 million senior secured floating rate notes offering by its subsidiaries, alongside a partial refinancing of its credit agreement. The company plans to use the proceeds to repay existing borrowings and refinance outstanding loans, with the transactions subject to market conditions. The notes will be guaranteed by Bausch + Lomb and secured by first priority liens, though there is no assurance of successful completion.

The most recent analyst rating on (BLCO) stock is a Hold with a $13.38 price target. To see the full list of analyst forecasts on Bausch + Lomb stock, see the BLCO Stock Forecast page.

Bausch + Lomb Launches €600M Notes Offering

On June 10, 2025, Bausch + Lomb Corporation announced the launch of a €600 million senior secured floating rate notes offering by its subsidiaries, alongside a partial refinancing of its credit agreement. The company aims to secure a $2.2 billion new term B loan facility and a new $800 million revolving credit facility to refinance existing loans and support general corporate purposes. The transactions, subject to market conditions, are designed to strengthen the company’s financial structure but are not guaranteed to be completed as planned.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Bausch + Lomb Launches €600 Million Notes Offering

On June 10, 2025, Bausch + Lomb Corporation announced the launch of a €600 million senior secured floating rate notes offering by its subsidiaries, alongside a partial refinancing of its credit agreement. The company plans to use the proceeds to repay existing borrowings and refinance outstanding loans, with the transactions subject to market conditions. The notes will be guaranteed by Bausch + Lomb and secured by first priority liens, though there is no assurance of successful completion.

The most recent analyst rating on (BLCO) stock is a Hold with a $13.38 price target. To see the full list of analyst forecasts on Bausch + Lomb stock, see the BLCO Stock Forecast page.

Bausch + Lomb Shareholders Approve Executive Compensation

At the Annual Meeting of Shareholders on May 21, 2025, Bausch + Lomb Corporation‘s shareholders voted on three proposals. The election of directors resulted in the appointment of several individuals to the Board of Directors, who will serve until the 2026 Annual Meeting. Additionally, the shareholders approved the executive compensation on a non-binding advisory basis.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Bausch + Lomb’s New Board Agreements Announced

On May 19, 2025, Bausch Health Companies Inc., the majority shareholder of Bausch + Lomb Corporation, entered into letter agreements with the Icahn Group, Paulson Group, and Kavanagh Group. These agreements stipulate that if any of these groups engage in specified actions, they must resign from the boards of both Bausch Health and Bausch + Lomb. The agreements also include provisions for voting on board nominees, aiming to maintain stability in board representation.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.